Skip to content
Clinical Trials – home

Wojewodzki Szpital Spec im. sw. Rafala w Czerwonej Gorze Swietokrzyskie Centrum Chorob Pluc

Verified siteinfoFast reply

Poland Ul. Czerwona Gora 10, 26-060 Checiny, Poland

  • 6 trials recruiting
  • Asthma · Chronic obstructive pulmonary disease · Hypereosinophilic syndrome
  • Adults and children

About Specializations

Wojewodzki Szpital Spec im. sw. Rafala w Czerwonej Gorze Swietokrzyskie Centrum Chorob Pluc in Checiny, Poland specialises in clinical trials of conditions such as Asthma, Chronic obstructive pulmonary disease, Hypereosinophilic syndrome, Non-small cell lung cancer stage I, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory Medicine

The medical center is at the forefront of respiratory medicine, focusing on innovative treatments for chronic respiratory conditions. The center's research is particularly concentrated on reducing dependency on oral corticosteroids in patients with severe asthma.

  • Oral Corticosteroid Dependent Asthma
  • Advanced Asthma Management
  • Biologic Therapies for Asthma

Through its cutting-edge research, the center is pioneering new approaches to manage asthma, aiming to improve patient outcomes by minimizing the need for long-term corticosteroid use.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Czerwona Gora 1026-060 ChecinyPoland
Recruiting now
6 trials
Conditions studied
4
Partner status
Verified site

More sites in ChecinyPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

13 clinical trials

Asthma

Recruiting

Safety and Tolerability of Benralizumab in Patients with HES, EGPA, or Asthma Who Completed a Prior Study

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Asthma

Recruiting

Study to evaluate the long-term safety and effectiveness of lunsekimig in adults with moderate to severe asthma

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of AZD6793 tablets to reduce flare-ups in adults with moderate to very severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Asthma

Not yet recruiting

Study comparing fluticasone furoate and vilanterol inhalation powder with BREO ELLIPTA in adults with asthma to evaluate their therapeutic equivalence and safety

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Fluticasone Furoate
  • Sponsor:Sandoz Private Limited

Asthma

Not recruiting

Study on the Effects of Lunsekimig (SAR443765) in Adults with High-Risk Asthma Not Eligible for Biologic Treatment

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Study of Depemokimab and Prednisolone in Adults with Hypereosinophilic Syndrome (HES)

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol in Patients Aged 40-80 with Chronic Obstructive Pulmonary Disease (COPD)

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Study of benralizumab compared to placebo for treatment of patients with Hypereosinophilic Syndrome (HES)

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Asthma

Not recruiting

Study on Tezepelumab for Reducing Steroid Use in Adults with Steroid-Dependent Asthma

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.